Check Out SeaStar Medical Holding Corporation (ICU)’s Trade Data Rather Than the Analysts’ Views

SeaStar Medical Holding Corporation (NASDAQ: ICU) stock fell -6.03% on Wednesday to $0.57 against a previous-day closing price of $0.61. With 0.38 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.54 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.5830 whereas the lowest price it dropped to was $0.5551. The 52-week range on ICU shows that it touched its highest point at $22.00 and its lowest point at $0.55 during that stretch. It currently has a 1-year price target of $5.00.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ICU was down-trending over the past week, with a drop of -3.32%, but this was down by -72.58% over a month. Three-month performance dropped to -80.26% while six-month performance fell -85.49%. The stock lost -94.35% in the past year, while it has lost -86.09% so far this year. A look at the trailing 12-month EPS for ICU yields -1.81 with Next year EPS estimates of -1.26. For the next quarter, that number is -0.25. This implies an EPS growth rate of -400.70% for this year and 8.00% for next year.

Float and Shares Shorts:

At present, 13.45 million ICU shares are outstanding with a float of 3.06 million shares on hand for trading. On May 14, 2023, short shares totaled 0.11 million, which was 0.79% higher than short shares on Apr 13, 2023. In addition to Mr. Eric Schlorff as the firm’s CEO, Pres & Exec. Director, Dr. H. David Humes M.D. serves as its Co-Founder and Managing Director.

Institutional Ownership:

Through their ownership of 10.09% of ICU’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.25% of ICU, in contrast to 22.82% held by mutual funds. Shares owned by individuals account for 0.29%. As the largest shareholder in ICU with 4.69% of the stake, Cohen & Company Financial Managem holds 623,400 shares worth 623,400. A second-largest stockholder of ICU, Hudson Bay Capital Management LP, holds 250,000 shares, controlling over 1.88% of the firm’s shares. SFMG LLC is the third largest shareholder in ICU, holding 43,888 shares or 0.33% stake. With a 0.10% stake in ICU, the Fidelity Extended Market Index Fu is the largest stakeholder. A total of 12,590 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.08% of ICU stock, is the second-largest Mutual Fund holder. It holds 9,979 shares valued at 21455.0. Lumyna – MW TOPS UCITS Fund holds 0.04% of the stake in ICU, owning 5,090 shares worth 10944.0.


An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, ICU reported revenue of $0.00 and operating income of -$1.31M. Over the past year, revenue came in at $0.00 while operating income stood at -$4.32M. It generated -$902.00k net income for the quarter, which came to -$4.33M over the last twelve months. The EBITDA in the recently reported quarter was -$1.31M and diluted EPS was -$0.12. EBITDA for the full year was -$4.32M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ICU since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ICU analysts setting a high price target of $5.00 and a low target of $5.00, the average target price over the next 12 months is $5.00. Based on these targets, ICU could surge 777.19% to reach the target high and rise by 777.19% to reach the target low. Reaching the average price target will result in a growth of 777.19% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded ICU stock several times over the past three months with 8 Buys and 0 Sells. In these transactions, 125,431 shares were bought while 0 shares were sold. The number of buy transactions has increased to 19 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 12,982,735 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *